Portfolio company
Abologix
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops monoclonal antibody therapeutics to treat drug-resistant lymphomas and solid tumours for cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Abalos Therapeutics
This company develops arenavirus-based immuno-virotherapies to treat solid tumours and metastases for patients with cancer.
Arch Oncology
This biotechnology firm develops antibody therapies to treat patients with solid tumours and hematologic malignancies.
CellmAbs
This biotech company develops monoclonal antibodies and adoptive cell therapies to treat oncology patients with solid tumours.
Abalone Bio
This company develops functional antibody drugs for pharmaceutical partners using synthetic biology and machine learning to treat challenging diseases.
Tacalyx
This company develops antibody-based therapeutics targeting tumour associated carbohydrate antigens for the treatment of solid tumours in cancer patients.
Northern Biologics
This company develops antibody-based therapeutics targeting the tumour microenvironment to treat patients with cancer and fibrosis.
Solu Therapeutics
This biotechnology company develops antibody-based medicines that target and eliminate disease-driving cells to treat patients with cancer and immunological disorders.
Aboleris Pharma
This biopharmaceutical company develops immunomodulatory antibodies to treat autoimmune diseases and organ transplantation rejection for patients requiring restored immune tolerance.